https://doi.org/10.4081/monaldi.2022.2388
Alectinib rescue therapy in advanced ALK rearranged lung adenocarcinoma: a case report
Submitted: July 27, 2022
Accepted: September 14, 2022
Published: September 20, 2022
Accepted: September 14, 2022
Abstract Views: 1112
PDF: 218
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) that is approved as first-line treatment in adult patients with ALK-positive non-small cell lung cancer (NSCLC) and as second-line in patients previously treated with crizotinib, and has been shown in the literature to significantly prolong progression-free survival compared to chemotherapy in patients with advanced non-small cell lung cancer. The authors describe a clinical case of a 24-year-old woman with malignant massive pleural effusion caused by ALK rearranged pulmonary adenocarcinoma with pleural and pericardial metastasis, in which, despite a dramatic clinical debut, the correct and timely management of the diagnostic and therapeutic path allowed for extraordinary therapeutic success.
Porcel JM, Gasol A, Bielsa S, et al. Clinical features and survival of lung cancer patients with pleural effusions. Respirology 2015;20:654-9.
DOI: https://doi.org/10.1111/resp.12496
Comella P, Frasci G, De Cataldis G, et al. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano. Br J Cancer 1996;74:1805-11.
DOI: https://doi.org/10.1038/bjc.1996.634
Cattaneo F, Guerra G, Parisi M, et al. Expression of formyl-peptide receptors in human lung carcinoma. Anticancer Res 2015;35:2769-74.
Bianco A, Perrotta F, Barra G, et al. Prognostic factors and biomarkers of responses to immune checkpoint inhibitors in lung cancer. Int J Mol Sci 2019;20:4931.
DOI: https://doi.org/10.3390/ijms20194931
Perrotta F, Rocco D, Vitiello F, et al. Immune checkpoint blockade for advanced NSCLC: A new landscape for elderly patients. Int J Mol Sci 2019;20:2258.
DOI: https://doi.org/10.3390/ijms20092258
Cameron LB, Hitchen N, Chandran E, et al. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cochrane Database Syst Rev 2022;1:CD013453.
DOI: https://doi.org/10.1002/14651858.CD013453.pub2
Golding B, Luu A, Jones R, Viloria-Petit AM. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer 2018;17:52.
DOI: https://doi.org/10.1186/s12943-018-0810-4
Moore DA, Benafif S, Poskitt B, et al. Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancer. Lung Cancer 2021;161:55-9.
DOI: https://doi.org/10.1016/j.lungcan.2021.08.008
Doxtader EE, Cheng YW, Zhang Y. Molecular testing of non-small cell lung carcinoma diagnosed by endobronchial ultrasound-guided transbronchial fine-needle aspiration: The Cleveland clinic experience. Arch Pathol Lab Med 2019;143:670-6.
DOI: https://doi.org/10.5858/arpa.2017-0184-RA
Perrotta F, Nankivell M, Adizie JB, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for PD-L1 testing in non-small cell lung cancer. Chest 2020;158:1230-9.
DOI: https://doi.org/10.1016/j.chest.2020.04.059
Ando K, Akimoto K, Sato H, et al. Brigatinib and alectinib for ALK rearrangement-positive advanced non-small cell lung cancer with or without central nervous system metastasis: A systematic review and network meta-analysis. Cancers (Basel) 2020;12:942.
DOI: https://doi.org/10.3390/cancers12040942
Serritella AV, Bestvina CM. Anaplastic lymphoma kinase mutation-positive non-small cell lung cancer. Thorac Surg Clin 2020;30:137-46.
DOI: https://doi.org/10.1016/j.thorsurg.2019.12.001
How to Cite
Cesaro, Cristiano, Umberto Caterino, Fabio Perrotta, Umberto Masi, Alessandra Cotroneo, Roberta Cianci, Enzo Zamparelli, Flavio Cesaro, Dario Amore, and Danilo Rocco. 2022. “Alectinib Rescue Therapy in Advanced ALK Rearranged Lung Adenocarcinoma: A Case Report”. Monaldi Archives for Chest Disease 93 (3). https://doi.org/10.4081/monaldi.2022.2388.
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Giampaolo Scorcu, Annarita Pilleri, Treatment of heart failure in the elderly: Which drugs are essential and which should be avoided , Monaldi Archives for Chest Disease: Vol. 88 No. 2 (2018)
- C.A. Jiménez-Ruiz, K.O. Fagerström, Smoking cessation treatment for COPD smokers: the role of pharmacological interventions , Monaldi Archives for Chest Disease: Vol. 79 No. 1 (2013): Pulmonary series
- Igor Sergeevich Mamenko, Igor V. Vasilev, Roman V. Simonov, Anna S. Zakharova, Pavel V. Gavrilov, Ivetta V. Dvorakovskaya, Tatiana A. Novitskaya, Petr K. Yablonskiy, Probe-based confocal laser endomicroscopy in the diagnosis of diffuse cystic lung disease in Sjögren’s syndrome , Monaldi Archives for Chest Disease: Vol. 94 No. 3 (2024)
- Chiara Francesca Carraro, Two cases of COPD benefitting from therapy with roflumilast , Monaldi Archives for Chest Disease: Vol. 79 No. 3-4 (2013): Pulmonary series - Supplement 1
- Nicola Cosentino, Jeness Campodonico, Valentina Milazzo, Katia Celentano, Marco Moltrasio, Pompilio Faggiano, Giancarlo Marenzi, Extended dual antiplatelet therapy after acute myocardial infarction. Current evidence and future perspectives , Monaldi Archives for Chest Disease: Vol. 89 No. 2 (2019)
- Bruno De Piccoli, Dante Eduardo Rivaben, Giuseppe Favretto, Unexpected early obstruction of a biological aortic valve prosthesis , Monaldi Archives for Chest Disease: Vol. 82 No. 1 (2014): Cardiac series
- Maurizio Giuseppe Abrignani, Vincenzo Abrignani, Thromboembolic and hemorrhagic risk stratification in patients with atrial fibrillation. Part II: hemorrhagic risk and guidelines recommendations , Monaldi Archives for Chest Disease: Vol. 80 No. 3 (2013): Cardiac series
- R. Luzzati, M. Confalonieri, A. Cazzadori, P. Della Loggia, R. Cifaldi, C. Fabris, M. Biolo, M. Borelli, C. Longo, E. Concia, Prolonged hospitalisation for immigrants and high risk patients with positive smear pulmonary tuberculosis , Monaldi Archives for Chest Disease: Vol. 75 No. 2 (2011): Pulmonary series
- A. Corrado, T. Renda, S. Bertini, Long-Term Oxygen Therapy in COPD: evidences and open questions of current indications , Monaldi Archives for Chest Disease: Vol. 73 No. 1 (2010): Pulmonary series
- I.B. Oliva, F. Cortopassi, C.L. Rochester, A.N. Rubinowitz, Combined pulmonary fibrosis and emphysema syndrome: a radiologic perspective , Monaldi Archives for Chest Disease: Vol. 75 No. 4 (2011): Pulmonary series
<< < 14 15 16 17 18 19 20 21 22 23 > >>
You may also start an advanced similarity search for this article.
